EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best–worst scaling task

Rebecca Kathleen Metcalfe iD, Sophia Dobischok, Nick Bansback iD, Scott MacDonald, David Byres, Julie Lajeunesse, Scott Harrison, Bryce Koch, Blue Topping, Terry Brock, Julie Foreman, Martin Schechter und 1 weitere

Addiction · 2024

DOI: 10.1111/add.16620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, 2024. Verfasst von Rebecca Kathleen Metcalfe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advancing Health Outcomes, Providence Health Care, St. Paul's Hospital, Vancouver, Canada. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Patient Preference, Opiate Substitution Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canada Foundation for Innovation, Canada Research Chairs, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Clinical trials support injectable opioid agonist treatment (iOAT) for individuals with opioid use disorder (OUD) for whom other pharmacological management approaches are not well‐suited. However, despite substantial research indicating that person‐centered care improves engagement, retention and health outcomes for individuals with OUD, structural requirements (e.g. drug policies) often dictate how iOAT must be delivered, regardless of client preferences. This study aimed to quantify clients' iOAT delivery preferences to improve client engagement and retention.

Design

Cross‐sectional preference elicitation survey.

Setting

Metro Vancouver, British Columbia, Canada.

Participants

124 current and former iOAT clients.

Measurements

Participants completed a demographic questionnaire package and an interviewer‐led preference elicitation survey (case 2 best–worst scaling task). Latent class analysis was used to identify distinct preference groups and explore demographic differences between preference groups.

Findings

Most participants ( n = 100; 81%) were current iOAT clients. Latent class analysis identified two distinct groups of client preferences: (1) autonomous decision‐makers ( n = 73; 59%) and (2) shared decision‐makers ( n = 51; 41%). These groups had different preferences for how medication type and dosage were selected. Both groups prioritized access to take‐home medication (i.e. carries), the ability to set their own schedule, receiving iOAT in a space they like and having other services available at iOAT clinics. Compared with shared decision‐makers, fewer autonomous decision‐makers identified as a cis‐male/man and reported flexible preferences.

Conclusions

Injectable opioid agonist treatment (iOAT) clients surveyed in Vancouver, Canada, appear to prefer greater autonomy than they currently have in choosing OAT medication type, dosage and treatment schedule.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersPatient PreferenceOpiate Substitution TreatmentHumansMaleFemaleCross-Sectional StudiesAdultBritish ColumbiaMiddle AgedAnalgesics, OpioidInjectionsDecision Making, SharedSurveys and QuestionnairesLatent Class Analysis

Stichwörter der Autor:innen

best worst scalingdiacetylmorphinehydromorphoneinjectable opioid agonist treatmentopioid use disorderpatient preferencesperson‐centered care

Substanzen

Analgesics, Opioid

Autor:innen und Institutionen

  • Centre for Advancing Health Outcomes, Providence Health Care, St. Paul's Hospital, Vancouver, Canada.
  • Department of Education and Counselling Psychology, McGill University, Montreal, Canada.
  • School of Population and Public Health, University of British Columbia, Vancouver, Canada.
  • Providence Health Care, Providence Crosstown Clinic, Vancouver, Canada.
  • Provincial Health Services Authority, Vancouver, Canada.
  • Island Health, Victoria, BC, Canada.

ORCID-Profile: Rebecca Kathleen Metcalfe, Nick Bansback

Förderung

  • Canada Foundation for Innovation
  • Canada Research Chairs
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Metcalfe, R. K., Dobischok, S., Bansback, N., MacDonald, S., Byres, D., Lajeunesse, J., Harrison, S., Koch, B., Topping, B., Brock, T., Foreman, J., Schechter, M., & Oviedo-Joekes, E. (2024). Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best–worst scaling task. Addiction. https://doi.org/10.1111/add.16620

Vancouver

Metcalfe RK, Dobischok S, Bansback N, MacDonald S, Byres D, Lajeunesse J, et al. Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best–worst scaling task. Addiction. 2024. doi:10.1111/add.16620

BibTeX
@article{Metcalfe2024,
  author = {Metcalfe, Rebecca Kathleen and Dobischok, Sophia and Bansback, Nick and MacDonald, Scott and Byres, David and Lajeunesse, Julie and Harrison, Scott and Koch, Bryce and Topping, Blue and Brock, Terry and Foreman, Julie and Schechter, Martin and Oviedo-Joekes, Eugenia},
  title = {Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best–worst scaling task},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16620}
}
Kostenlos starten →